Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer

被引:114
作者
Kotzerke, J [1 ]
Volkmer, BG
Neumaier, B
Gschwend, JE
Hautmann, RE
Reske, SN
机构
[1] Univ Ulm, Dept Nucl Med, D-89069 Ulm, Germany
[2] Univ Ulm, Dept Urol, D-89069 Ulm, Germany
关键词
acetate; positron emission tomography; prostate cancer; recurrence;
D O I
10.1007/s00259-002-0882-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
We investigated the potential of [C-11]acetate positron emission tomography (PET) to detect local recurrence in prostate cancer (PCA) in patients with increasing PSA following complete prostatectomy. total of 31 patients were studied and compared with the results of transrectal ultrasound (TRUS) combined with biopsy and clinical follow-up. Whole-body PET scan was performed 5 min after injection of 0.8 GBq [C-11]acetate and completed within 1 h. Focally increased tracer uptake below the urinary bladder or in an abdominal lymph node region was considered as relapse. TRUS followed by biopsy verified recurrence in 18 patients and ruled it out in 13 patients. PET demonstrated local recurrence in 15 out of the aforementioned 18 patients. PET also demonstrated distant lymph node involvement and bone metastases in five patients each. No focal [C-11]acetate uptake was demonstrated in the prostate bed in patients with negative biopsy. These patients had no evidence of disease during 6 months of follow-up. In the subgroup of patients with PSA <2.0 ng/ml (n=8), five patients had positive PET findings, with four of them verified by biopsy. It is concluded that [C-11]acetate PET is a promising new tool for the diagnosis of PCA recurrence and can influence patient management.
引用
收藏
页码:1380 / 1384
页数:5
相关论文
共 10 条
[1]  
Dienel GA, 2001, J NUCL MED, V42, P1243
[2]   Management of patients with climbing PSA values after curative therapy [J].
Fichtner, J ;
Miller, K .
UROLOGE A, 2000, 39 (05) :475-482
[3]  
Hara T, 2002, J NUCL MED, V43, P187
[4]  
Hara T, 1998, J NUCL MED, V39, P990
[5]   Experience with carbon-11 choline positron emission tomography in prostate carcinoma [J].
Kotzerke, J ;
Prang, J ;
Neumaier, B ;
Volkmer, B ;
Guhlmann, A ;
Kleischmidt, K ;
Hautmann, R ;
Reske, SN .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (09) :1415-1419
[6]  
Oyama N, 2002, J NUCL MED, V43, P181
[7]   Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer [J].
Pisansky, TM ;
Kozelsky, TF ;
Myers, RP ;
Hillman, DW ;
Blute, ML ;
Buskirk, SJ ;
Cheville, JC ;
Ferrigni, RG ;
Schild, SE .
JOURNAL OF UROLOGY, 2000, 163 (03) :845-850
[8]  
SHREVE P, 1995, J NUCL MED, V36, P1595
[9]   11C-acetate clearance in nasopharyngeal carcinoma [J].
Yeh, SH ;
Liu, RS ;
Wu, LC ;
Yen, SH ;
Chang, CW ;
Chen, KY .
NUCLEAR MEDICINE COMMUNICATIONS, 1999, 20 (02) :131-134
[10]   Characterization of acetate metabolism in tumor cells in relation to cell proliferation: Acetate metabolism in tumor cells [J].
Yoshimoto, M ;
Waki, A ;
Yonekura, Y ;
Sadato, N ;
Murata, T ;
Omata, N ;
Takahashi, N ;
Welch, MJ ;
Fujibayashi, Y .
NUCLEAR MEDICINE AND BIOLOGY, 2001, 28 (02) :117-122